273 related articles for article (PubMed ID: 20006861)
1. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma.
Johnson TV; Abbasi A; Owen-Smith A; Young A; Ogan K; Pattaras J; Nieh P; Marshall FF; Master VA
J Urol; 2010 Feb; 183(2):480-5. PubMed ID: 20006861
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
[TBL] [Abstract][Full Text] [Related]
3. Re: Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma: T. V. Johnson, A. Abbasi, A. Owen-Smith, A. Young, K. Ogan, J. Pattaras, P. Nieh, F. F. Marshall and V. A. Master J Urol 2010; 183: 480-485.
Canda AE
J Urol; 2010 Oct; 184(4):1570-1; author reply 1571. PubMed ID: 20728182
[No Abstract] [Full Text] [Related]
4. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score.
Iimura Y; Saito K; Fujii Y; Kumagai J; Kawakami S; Komai Y; Yonese J; Fukui I; Kihara K
J Urol; 2009 Mar; 181(3):1004-12; discussion 1012. PubMed ID: 19150550
[TBL] [Abstract][Full Text] [Related]
5. Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma.
Johnson TV; Abbasi A; Owen-Smith A; Young AN; Kucuk O; Harris WB; Osunkoya AO; Ogan K; Pattaras J; Nieh PT; Marshall FF; Master VA
Urology; 2010 Sep; 76(3):766.e1-5. PubMed ID: 20394975
[TBL] [Abstract][Full Text] [Related]
6. Editorial comment.
Campbell SC; Lane BR
J Urol; 2010 Feb; 183(2):485; discussion 485. PubMed ID: 20006871
[No Abstract] [Full Text] [Related]
7. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
8. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
9. Intratumor C-reactive protein as a biomarker of prognosis in localized renal cell carcinoma.
Johnson TV; Ali S; Abbasi A; Kucuk O; Harris WB; Ogan K; Pattaras J; Nieh PT; Marshall FF; Osunkoya AO; Master VA
J Urol; 2011 Oct; 186(4):1213-7. PubMed ID: 21849188
[TBL] [Abstract][Full Text] [Related]
10. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma.
Komai Y; Saito K; Sakai K; Morimoto S
BJU Int; 2007 Jan; 99(1):77-80. PubMed ID: 16956357
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients.
Karakiewicz PI; Hutterer GC; Trinh QD; Jeldres C; Perrotte P; Gallina A; Tostain J; Patard JJ
Cancer; 2007 Sep; 110(6):1241-7. PubMed ID: 17639589
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
13. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of erythrocyte polyamine in the post-nephrectomy stratification of renal cell carcinoma specific mortality.
Bigot P; Lughezzani G; Karakiewicz P; Perrotte P; Rioux-Leclercq N; Catros-Quemener V; Bouet F; Moulinoux JP; Cipolla B; Patard JJ
J Urol; 2010 Feb; 183(2):486-91. PubMed ID: 20006872
[TBL] [Abstract][Full Text] [Related]
15. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.
Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K
J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer.
Ramsey S; Lamb GW; Aitchison M; McMillan DC
BJU Int; 2008 Apr; 101(8):959-63. PubMed ID: 18190639
[TBL] [Abstract][Full Text] [Related]
17. Adrenal sparing surgery during radical nephrectomy in patients with renal cell cancer: a new algorithm.
Paul R; Mordhorst J; Busch R; Leyh H; Hartung R
J Urol; 2001 Jul; 166(1):59-62. PubMed ID: 11435823
[TBL] [Abstract][Full Text] [Related]
18. Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma.
Ito K; Yoshii H; Sato A; Kuroda K; Asakuma J; Horiguchi A; Sumitomo M; Asano T
J Urol; 2011 Aug; 186(2):430-5. PubMed ID: 21679988
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.
Yoo C; Song C; Hong JH; Kim CS; Ahn H
J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101
[TBL] [Abstract][Full Text] [Related]
20. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
